ClinicalTrials.gg
CompletedNCT00653523Updated May 21, 2024Results posted

Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)

A Phase 3 interventional study of Ezetimibe and Simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2007, registered Apr 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
47th of 97
151 · median 148
Started
2007
with 15 others
Phase 3
50 of 98
1 open now
Registered
44th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 47th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 44th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with hypercholesterolemia who satisfy the following criteria:

    • Patients who have used any of the following HMG-CoA reductase inhibitors (hereinafter referred to as "statins") for 4 weeks or longer before the start of the observation period and whose LDL-cholesterol level during the treatment had not reached lipid management target indicated below
    • Age: 20 years of age or older (at the time of obtaining )
    • Sex: both males and females
    • Inpatient/outpatient: Out-patients

Exclusion criteria

Exclusion Criteria:

  • Patients for whom any of the following is applicable:

    • Patients whose fasted triglyceride level measured at the start of the observation period or the treatment period exceeds 500 mg/dL
    • Patients with homozygous familial hypercholesterolemia
    • Patients with creatine phosphokinase (CPK) > 2x (ULN) measured at the start of the observation period or the treatment period.
    • Patients with serious hepatic disorder, or patients with (ALT) or aspartate aminotransferase (AST) > 2x ULN measured at the start of the observation period or the treatment period.
    • Patients with a history of to any ingredient of ezetimibe tablets or simvastatin tablets
    • Pregnant, nursing women, women who may be pregnant, or patients wishing to be pregnant during the study.
    • Patients who have discontinued use of serum lipid lowering agents for less than 4 weeks at the start of the treatment period (8 weeks in the case of probucol). (However, if the patient had taken a serum lipid lowering agent before the test conducted at the start of the observation period, a period of discontinuation of 27 days, or 55 days in the case of probucol, is allowed.)
    • Patients who are using cyclosporine from after the start of the observation period
    • Patients who are using any of the following drug from after the start of the observation period: itraconazole, miconazole, atazanavir, saquinavir mesilate
    • Patients with a history of ezetimibe use
    • Patients with hyperlipidemia associated with the following diseases:

      • Hypothyroidism
      • Obstructive gall bladder or biliary disease
      • Chronic renal failure
      • Pancreatitis
    • Patients with hyperlipidemia associated with concomitant use of drugs having adverse effect on serum lipids, etc
    • Patients who have received an drug within 4 weeks of the start of the observation period
    • Other patients deemed not appropriate for study entry by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Ezetimibe + Simvastatin

    Ezetimibe 10 mg + Simvastatin 20 mg

    Drug: Ezetimibe · Drug: Simvastatin

Interventions

  • Ezetimibe 10 mg once daily

    Also known as: SCH 58235

  • Simvastatin 20 mg daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events and Adverse Reactions

    An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified. That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered. Any adverse event that was treatment-related was considered an adverse reaction.

    Time frame: Throughout 1 year of study

07

Results

Posted Jun 30, 2010

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe + Simvastatin
Started151
Completed132
Not completed19
Withdrew: Drop in low density lipoprotein (1)2
Withdrew: Elevated creatine phosphokinase (2)1
Withdrew: Adverse event7
Withdrew: Withdrawal by subject6
Withdrew: Elevated alanine aminotransferase (3)2
Withdrew: Adverse reaction did not improve (4)1

Outcome measures

PrimaryNumber of Participants With Adverse Events and Adverse Reactions

An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified. That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered. Any adverse event that was treatment-related was considered an adverse reaction.

Time frame:
Throughout 1 year of study
Reported as:
Number · Participants
Number of Participants With Adverse Events and Adverse Reactions
ParticipantsEzetimibe + Simvastatin
Adverse Events143
Adverse Reactions36

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe+Simvastatin—17/151 (11.3%)127/151 (84.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventEzetimibe+Simvastatin
CORONARY ARTERY RESTENOSISInjury, poisoning and procedural complications3/151
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/151
ANGINA UNSTABLECardiac disorders1/151
HYPERTROPHIC CARDIOMYOPATHYCardiac disorders1/151
EYE PAINEye disorders1/151
PNEUMONIAInfections and infestations1/151
IN-STENT CORONARY ARTERY RESTENOSISInjury, poisoning and procedural complications1/151
DIABETES MELLITUS INADEQUATE CONTROLMetabolism and nutrition disorders1/151
ROTATOR CUFF SYNDROMEMusculoskeletal and connective tissue disorders1/151
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/151
Most frequent other events
Showing 10 of 22
Most frequent other events
EventEzetimibe+Simvastatin
NASOPHARYNGITISInfections and infestations46/151
C-REACTIVE PROTEIN INCREASEDInvestigations41/151
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations27/151
ALANINE AMINOTRANSFERASE INCREASEDInvestigations26/151
MYOGLOBIN BLOOD INCREASEDInvestigations21/151
BRONCHITISInfections and infestations20/151
BACK PAINMusculoskeletal and connective tissue disorders17/151
ARTHRALGIAMusculoskeletal and connective tissue disorders15/151
GAMMA-GLUTAMYLTRANSFERASE INCREASEDInvestigations14/151
MUSCLE SPASMSMusculoskeletal and connective tissue disorders14/151

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ezetimibe + Simvastatin
Number151
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe + Simvastatin
Female82
Male69
Region of Enrollment
Region of Enrollment(participants)Ezetimibe + Simvastatin
Japan151
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2007 to primary completion in Jun 2009, 18 months.

Results were first posted in Jun 2010, 1 year after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 7, 2008
StartActual
Dec 1, 2007
Primary completionActual
Jun 1, 2009
CompletionActual
Jun 1, 2009
Results first posted
Jun 30, 2010
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00653523
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
Dec 1, 2007
Primary completion
Jun 1, 2009
Completion
Jun 1, 2009
Results posted
Jun 30, 2010
Last update
May 21, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion